DooU Review Canada 2026: Ozempic, Pricing and Is It Legit?

This review is based on publicly available information from DooU's platform, PocketPills corporate disclosures, LegitScript registry listings, and third-party patient review platforms as of June 2026. DooU is not an affiliate partner of WeightLossInjections.ca; this review carries no commercial relationship.

What Is DooU?

DooU is a Canadian telehealth platform focused on weight management, operating at doou.ca. It is a subsidiary of PocketPills, the online pharmacy that was acquired by Loblaw Companies Limited - the parent company of Shoppers Drug Mart, No Frills, Loblaws, and PC Health. This corporate lineage is relevant because it means DooU's pharmacy infrastructure runs through one of Canada's most heavily regulated and scrutinized pharmacy operations.

The Loblaw-PocketPills corporate chain provides DooU with infrastructure advantages that are difficult for independent telehealth startups to replicate: established insurer relationships (enabling direct billing), a licensed national pharmacy network, and regulatory standing built through years of retail pharmacy compliance. That context explains why DooU scores highest in the Pharmacy Credibility and Overall Trust Signals categories despite being a relatively newer brand in the GLP-1 telehealth category.

DooU holds LegitScript certification, the internationally recognized standard for online pharmacy legitimacy. LegitScript is the verification body used by Google, Meta, and Microsoft to approve pharmaceutical advertisers before they can run paid search or social advertising. Certification requires documented prescription practices, licensed pharmacist oversight, and demonstrated compliance with Canadian pharmacy law. Not all Canadian GLP-1 telehealth platforms maintain this certification.

As of June 2026, DooU has served more than 25,000 Canadians since launch. The platform employs physician specialists with training in weight management - a stated differentiator from general-practice telehealth platforms where the assessing clinician may have limited bariatric medicine experience. Clinical consultations are asynchronous: patients submit responses to structured intake questions and receive a clinical decision via messaging rather than a live video or phone appointment.

How DooU Works: Step by Step

DooU's intake process is designed to require less than five minutes to complete before it reaches a clinician. The model is fully asynchronous - there are no scheduled video calls, no phone appointments, and no time-sensitive booking windows. Here is the end-to-end sequence:

DooU Pricing and Fees

DooU uses a multi-layer fee structure that differs from the flat-rate model used by competitors like Felix Health and MyRocky. Understanding the full cost picture requires accounting for the setup fee, the initial assessment, recurring follow-up visit fees, and medication costs separately. This structure earns a lower Cost Transparency score because it takes more effort to calculate 12-month costs upfront.

To illustrate the 12-month cost difference, the table below assumes a patient starting on brand-name Ozempic (0.5 mg, approximately $220/month), attending four follow-up visits per year, and paying all required clinical fees. Medication costs are estimates and may vary by province and pharmacy.

The cost comparison illustrates the DooU pricing gap relative to flat-rate competitors. Over a standard 12-month treatment course with four follow-up visits, DooU patients pay approximately $246 more in clinical fees alone compared to Felix or MyRocky, both of which include ongoing support in their initial consultation fee. Patients requiring more frequent titration visits (six or more per year) would see this gap widen further.

Direct Insurance Billing - A Real Differentiator

DooU's direct insurance billing capability with select insurers is the most distinctive feature of the platform and deserves specific attention. In the Canadian GLP-1 telehealth landscape, the majority of platforms - including Felix Health, MyRocky, and Phoenix - do not directly bill private insurers. They issue receipts that you submit yourself through your benefits portal for potential reimbursement.

DooU's model works differently. Through the PocketPills pharmacy infrastructure and its established insurer relationships (built over years of retail pharmacy billing), DooU can submit claims on behalf of eligible patients directly to participating insurance plans. This means eligible patients may not need to pay the full medication cost upfront and wait for reimbursement - the insurer is billed directly at the point of dispensing.

This matters in practice for two categories of patients. First, patients whose group benefit plans cover GLP-1 medications but who have significant cash flow constraints - direct billing eliminates the out-of-pocket float period. Second, patients with plans that require pharmacy-level claims (rather than patient-submitted claims) - some employer benefit plans only process drug claims submitted through the dispensing pharmacy, which means platforms lacking pharmacy billing integration cannot facilitate coverage at all.

The limitation worth noting is that "select insurers" means not all plans are supported. DooU does not publish a comprehensive list of participating insurers on its public website. Patients should contact DooU directly before enrolling to confirm whether their specific plan is within the supported network. GLP-1 medications are also excluded from many standard drug benefit formularies, meaning insurance coverage cannot be assumed even with a direct-billing-capable pharmacy.

Province Coverage

DooU is available nationwide across all ten Canadian provinces and the three federal territories. This is among the broadest coverage footprints of any Canadian GLP-1 telehealth provider and directly reflects the national pharmacy infrastructure inherited from PocketPills.

Quebec coverage is a significant point of distinction. Quebec has distinct pharmacy regulations, French-language service requirements, and a separate provincial drug benefit regime (RAMQ) that creates substantial compliance complexity for telehealth platforms. Several major competitors - including Felix Health - do not currently operate in Quebec or New Brunswick. DooU's Loblaw-PocketPills infrastructure provides the regulatory standing to serve both provinces.

Medications Prescribed by DooU

DooU prescribes both injectable and oral GLP-1 medications, covering the full range of Health Canada-approved options for weight management. This breadth of prescribing is relatively unusual - several telehealth platforms focus exclusively on injectable semaglutide or tirzepatide.

The inclusion of Rybelsus (oral semaglutide) is particularly relevant for patients with needle aversion, injection-site reactions, or lifestyle situations where weekly injections are inconvenient. Oral semaglutide is less commonly offered on Canadian telehealth platforms - most focus on the injectable formulations where patient adherence data and clinical trial evidence are strongest.

DooU does not currently prescribe generic semaglutide (the Apotex generic launched in May 2026). Patients seeking the lowest-cost semaglutide option should note that Felix Health and MyRocky both offer generic semaglutide starting at approximately $149/month, which is substantially below the brand-name pricing available through DooU.

Patient Reviews

DooU holds a 4.0/5 rating on Trustpilot based on verified patient reviews as of June 2026. This places it behind MyRocky and Phoenix on third-party review sentiment but ahead of several other Canadian telehealth platforms. The review profile reflects a platform that performs well on core clinical outcomes but generates friction around billing transparency and the per-visit fee model.

Common positive themes in patient reviews: Fast onboarding, no requirement for existing bloodwork or physician referrals, accessible messaging support, and the convenience of a fully asynchronous process. Patients in Quebec and the territories specifically note DooU as one of their only accessible online options.

Common negative themes in patient reviews: Surprise at follow-up visit fees after the initial assessment - some patients report not fully understanding that the $50 per-visit charge accumulates over the treatment course. Shipping delays on medication were mentioned in a subset of reviews, though these appear to be isolated rather than systemic. A smaller number of reviews reference difficulty reaching clinical support during busy periods.

The 4.0/5 Trustpilot rating is a reasonable representation of a platform that delivers on its clinical promise but has room to improve on pricing communication. Competitors with higher ratings - MyRocky at the top of the market, Phoenix at 4.6/5 - tend to have cleaner fee structures that reduce billing-related dissatisfaction.

Who Should NOT Use DooU

Beyond medical contraindications, there are situational reasons DooU may not be the best fit. Patients who are cost-sensitive and anticipate needing frequent follow-up visits (more than four per year) will find DooU significantly more expensive than flat-rate competitors. Patients seeking generic semaglutide at $149/month should look at Felix Health or MyRocky instead. Patients who are not located in Quebec, the territories, or New Brunswick - and therefore have access to a full range of competitors - should compare options carefully before defaulting to DooU.

Pros and Cons

Verdict

DooU scores 7.4/10 in our independent assessment. That score reflects a platform with genuinely strong institutional underpinnings - Loblaw-PocketPills infrastructure, LegitScript certification, weight management specialists, and the only direct insurance billing in the Canadian GLP-1 telehealth space - but held back by a fee structure that is harder to model than competitors and a pricing floor that does not reach the $149/month generic semaglutide tier now available through Felix and MyRocky.

DooU is the strongest choice for three specific patient groups: Canadians in Quebec, New Brunswick, or the territories where competitor options are limited or unavailable; patients whose employer benefit plan covers GLP-1 medications and where direct insurance billing would materially reduce out-of-pocket costs; and patients who specifically want an oral GLP-1 option (Rybelsus) rather than an injectable.

For the majority of Canadians in the nine provinces where Felix, MyRocky, and other competitors operate, those platforms offer comparable clinical quality at lower 12-month cost - particularly if generic semaglutide is appropriate. DooU is a legitimate and well-governed option; it is not the most economical one.

Frequently Asked Questions

Is DooU legit?

Yes. DooU is a licensed Canadian telehealth platform operating under the PocketPills pharmacy infrastructure, which is owned by Loblaw Companies Limited. It holds LegitScript certification for its online pharmacy operations - the same certification standard required by Google and Meta to permit pharmaceutical advertisers on their platforms. DooU's clinical team includes physician specialists with weight management training. It is a legitimate and regulated service.

Does DooU serve Quebec?

Yes. DooU is available in all ten Canadian provinces including Quebec, as well as the Northwest Territories, Nunavut, and Yukon. This makes it one of the only GLP-1 telehealth platforms with true nationwide Canadian coverage. Felix Health, for comparison, does not currently serve Quebec or New Brunswick.

Does DooU accept insurance?

DooU offers direct insurance billing with select participating insurers - a differentiator from most Canadian GLP-1 telehealth competitors. However, the list of participating insurers is not published publicly, and GLP-1 medications are excluded from many standard drug formularies. Contact DooU directly before enrolling to confirm whether your specific benefit plan is supported and whether your plan covers GLP-1 medications for the weight management indication.

How fast can I get Ozempic through DooU?

DooU states that treatment can begin within 48 hours of completing the assessment for eligible patients. The intake assessment takes under five minutes and does not require bloodwork to get started. After clinical approval, the prescription is routed through the PocketPills pharmacy for dispensing. Physical delivery of medication takes an additional 2-5 business days depending on your province and postal code.

What does DooU cost per month?

DooU's clinical fees include a $45 one-time program setup fee, a $100 initial assessment, and $50 per follow-up visit thereafter. Medication costs are separate and range from approximately $180/month for oral semaglutide (Rybelsus) to $630/month for higher-dose tirzepatide (Mounjaro). For a patient on standard-dose Ozempic with four follow-up visits per year, the all-in annual cost including clinical fees and medication is approximately $2,985 - compared to roughly $2,739 for Felix or MyRocky, which include ongoing clinical support in their initial consultation fee.

Does DooU require a blood test to get started?

No. DooU does not require bloodwork to begin the assessment process. The initial intake is based on your self-reported health history and the clinical judgment of the reviewing physician specialist. Some patients may be asked to provide bloodwork as part of the clinical review depending on their health profile and the physician's assessment.